SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial - Rochlitz, C; Moos, R; Biger, M (J Clin Oncol, 2014)
(Suppl.)